To view this email as a web page, click here

Today's Rundown

Featured Story

Quench Bio hit by 'successful failure,' winds down ops in Twitter thread as tech sold off at auction

Quench Bio’s short journey has come to an end after the biotech startup found that its target was simply undruggable.

read more

Top Stories

From partner to part of the family: Takeda pulls the trigger on Maverick buyout

Takeda tapped Maverick Therapeutics and its T-cell engager platform in early 2017 to create new treatments for previously undruggable cancer targets. The $125 million deal also had a 5-year buyout option, which Takeda is now exercising for an undisclosed upfront fee and up to $525 million in development and regulatory milestones.

read more

Ex-Intercept CMO Campagna lands at immune regulation biotech Q32

Jason Campagna has taken up the chief medical officer position (CMO) at Q32 Bio. Campagna arrives at Q32 after a stint at Intercept Pharmaceuticals that saw him rise to the CMO role at the biotech.

read more

Valo Health grabs $110M top-up, bringing series B to $300M

Valo Health launched in September with $100 million and a couple of acquisitions under its belt to transform drug development and trim years off R&D timelines. Now, it’s topping up its coffers with $110 million from Koch Disruptive Technologies that will bankroll the development of its technology as well as the discovery and development of its drug programs.

read more

Ventyx bags $114M to test drugs against hot immunology targets

Ventyx Biosciences has exited stealth mode with $114 million to fund development of immunology programs. The venBio Partners-led financing will support a pipeline led by a S1P1R modulator that is in clinical development as a treatment for inflammatory bowel disease (IBD).

read more

Cue Health's COVID-19 cartridge test authorized for home use with no prescription

One year into the pandemic, the FDA has authorized its first molecular COVID-19 diagnostic that can be performed completely at home and purchased without a prescription.

read more

The top 10 drugs losing U.S. exclusivity in 2021

As drugmakers respond to the COVID-19 pandemic by developing vaccines and therapeutics, many of them are losing patent protection on older—and once lucrative—medicines. And generics makers are taking the opportunity to seize market share with cheaper copycats. Here's the 2021 list.

read more

Enrollment Showcase

Specialize Your Career in Pharmaceutical Outcomes

Learn about the Top 5-Ranked UF College of Pharmacy’s online graduate programs in pharmaceutical outcomes & policy. Select from five specializations, including the new pharmaceutical value assessment & communication option. Over half of graduates progress to a new role within one year. Register now.

Resources

Content Hub: Remarque Systems Resource Hub

Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. 

Guide: How to maximize your drug commercialization investments

Unlock product potential by making the most of your commercialization investments. 

Whitepaper: New Data: A Better Way to Run CHO Cell Culture Experiments

Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly.

eBook: Optimize Trial Performance with AI-enabled Technology & Advanced Analytics

Unlock competitive advantage with AI and advanced analytics.

Whitepaper: The Crush: How COVID-19 Is Impacting Mature Brand Revenue & Long-Term Value

Mature brands lost billions in revenue and value during COVID, but with the right strategy, pharma can rebound and reignite revenue. Learn How.

Whitepaper: Overcoming the hurdles of Real-World Data Access through a federated global network

Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. 

Free Infographic: The Future of Vaccine Development

Involved in vaccine development? Check out this timely infographic detailing the history of vaccines, key development milestones, and what challenges remain.

Whitepaper: 2021 Outlook for Cell-Based Therapies in Oncology: CAR-T Expansion & Beyond

A look ahead at how cell-based therapies in oncology will advance during 2021-22: research, regulatory, and commercial milestones.

Whitepaper: Seasonal Vaccine Manufacturing

While service directories are filled with CMOs claiming vaccine fill-finish experience, the logistical challenges resulting from seasonal product are unique and it is important that outsourcing partners can ensure quality and on-time delivery.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Content Hub: How to improve the virtual work you do every day

We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met.

Content Hub: Emerging Biotech Resource Center

A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule

Executive Summary: Manufacturing Strategies to Effectively Industrialize Autologous Cell Therapies

Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Whitepaper: Achieving a Successful Drug Product Technology Transfer

Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.

Whitepaper: The Art of Recognizing Clinical Supply Risk Factors

In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management.

eBook: Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

Events